Bone-Targeted Agents. Preventing Skeletal Complications in Prostate Cancer

Alicia K. Morgans*, Matthew R. Smith

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


In men, prostate cancer is the most common non-cutaneous malignancy and the second most common cause of cancer death. Skeletal complications occur at various points during the disease course, either due to bone metastases directly, or as an unintended consequence of androgen deprivation therapy (ADT). Bone metastases are associated with pathologic fractures, spinal cord compression, and bone pain and can require narcotics or palliative radiation for pain relief. ADT results in bone loss and fragility fractures. This review describes the biology of bone metastases, skeletal morbidity, and recent advances in bone-targeted therapies to prevent skeletal complications of prostate cancer.

Original languageEnglish (US)
Pages (from-to)533-546
Number of pages14
JournalUrologic Clinics of North America
Issue number4
StatePublished - Nov 2012


  • ADT
  • Bone
  • Prostate cancer
  • Side effects of therapy
  • Skeletal complications
  • Skeletal related events

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Bone-Targeted Agents. Preventing Skeletal Complications in Prostate Cancer'. Together they form a unique fingerprint.

Cite this